company background image
VXRT

VaxartNasdaqCM:VXRT Stock Report

Market Cap

US$882.9m

7D

-6.0%

1Y

-13.3%

Updated

02 Dec, 2021

Data

Company Financials +
VXRT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

VXRT Stock Overview

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.

Price History & Performance

Summary of all time highs, changes and price drops for Vaxart
Historical stock prices
Current Share PriceUS$6.69
52 Week HighUS$24.90
52 Week LowUS$4.86
Beta0.35
1 Month Change-7.21%
3 Month Change-23.19%
1 Year Change-13.34%
3 Year Change145.06%
5 Year Changen/a
Change since IPO-21.29%

Recent News & Updates

Nov 16

Vaxart: Differentiated Covid Oral Route Remains Viable

In an environment where injection-type vaccines are proving to offer somewhat reduced protection against the delta variant, the risks of being infected and transmitting the virus to others remain high. In this case, Vaxart's oral tablet vaccine, not to be confused with the antiviral pills being produced by Merck and Pfizer, does make a lot of sense for preventive purposes. This differentiation seems to have been ignored by the market, with Vaxart's shares trending lower. Considering potential sales of $1 billion, a target share price of $15 remains a moderate one, but it is better to remain prudent with the road leading to Phase 3 trials likely to be a long one. The implications of Vaxart's development could have a significant effect on Covid-19 progress, namely by encouraging a lot of people like myself to be orally inoculated instead of being jabbed again and again.

Oct 30

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

On Oct 26, Vaxart announced dosing of the first subject in their Phase 2 COVID-19 oral tablet vaccine trial. The company has also updated their corporate presentation recently. I take a close look at Vaxart's COVID-19 program and share my thoughts.

Oct 02

Vaxart: An Update

On Oct. 1, Merck announced their oral COVID pill reduces hospitalization or death by 50% and the company will seek EUA as soon as possible. Merck's good news seemed to cause a double-digit % stock price drop in COVID vaccine developers, including VXRT. VXRT's COVID program is still on, but with an incredibly slow speed and an apparent lack of focus.

Shareholder Returns

VXRTUS BiotechsUS Market
7D-6.0%-1.4%-3.5%
1Y-13.3%1.8%19.4%

Return vs Industry: VXRT underperformed the US Biotechs industry which returned 1.8% over the past year.

Return vs Market: VXRT underperformed the US Market which returned 19.4% over the past year.

Price Volatility

Is VXRT's price volatile compared to industry and market?
VXRT volatility
VXRT Average Weekly Movement7.7%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: VXRT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: VXRT's weekly volatility has decreased from 19% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a28Andy Floroiuhttps://vaxart.com

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

Vaxart Fundamentals Summary

How do Vaxart's earnings and revenue compare to its market cap?
VXRT fundamental statistics
Market CapUS$882.86m
Earnings (TTM)-US$63.57m
Revenue (TTM)US$1.17m

715.5x

P/S Ratio

-13.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VXRT income statement (TTM)
RevenueUS$1.17m
Cost of RevenueUS$41.81m
Gross Profit-US$40.64m
ExpensesUS$22.93m
Earnings-US$63.57m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.51
Gross Margin-3,461.33%
Net Profit Margin-5,414.57%
Debt/Equity Ratio0%

How did VXRT perform over the long term?

See historical performance and comparison

Valuation

Is Vaxart undervalued compared to its fair value and its price relative to the market?

4.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: VXRT ($6.69) is trading above our estimate of fair value ($1.16)

Significantly Below Fair Value: VXRT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: VXRT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: VXRT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VXRT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VXRT is overvalued based on its PB Ratio (4.1x) compared to the US Biotechs industry average (2.8x).


Future Growth

How is Vaxart forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

74.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VXRT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: VXRT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: VXRT's is expected to become profitable in the next 3 years.

Revenue vs Market: VXRT's revenue (84.3% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: VXRT's revenue (84.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VXRT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Vaxart performed over the past 5 years?

-35.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VXRT is currently unprofitable.

Growing Profit Margin: VXRT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VXRT is unprofitable, and losses have increased over the past 5 years at a rate of 35.2% per year.

Accelerating Growth: Unable to compare VXRT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VXRT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: VXRT has a negative Return on Equity (-31.02%), as it is currently unprofitable.


Financial Health

How is Vaxart's financial position?


Financial Position Analysis

Short Term Liabilities: VXRT's short term assets ($192.3M) exceed its short term liabilities ($12.6M).

Long Term Liabilities: VXRT's short term assets ($192.3M) exceed its long term liabilities ($23.6M).


Debt to Equity History and Analysis

Debt Level: VXRT is debt free.

Reducing Debt: VXRT currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VXRT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: VXRT has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 30.8% each year.


Dividend

What is Vaxart current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VXRT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VXRT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VXRT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VXRT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VXRT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Andy Floroiu (48 yo)

1.5yrs

Tenure

US$2,546,628

Compensation

Mr. Cezar Andrei Floroiu, also known as Andy, M.B.A., also serves as the Chief Executive Officer and Principal Financial Officer at Vaxart, Inc. since June 14, 2020 and serves as its Director since April 2...


CEO Compensation Analysis

Compensation vs Market: Andy's total compensation ($USD2.55M) is about average for companies of similar size in the US market ($USD2.36M).

Compensation vs Earnings: Insufficient data to compare Andy's compensation with company performance.


Leadership Team

Experienced Management: VXRT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: VXRT's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.6%.


Top Shareholders

Company Information

Vaxart, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Vaxart, Inc.
  • Ticker: VXRT
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$882.865m
  • Shares outstanding: 125.50m
  • Website: https://vaxart.com

Number of Employees


Location

  • Vaxart, Inc.
  • 170 Harbor Way
  • Suite 300
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 23:42
End of Day Share Price2021/12/02 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.